Company news

Castle Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting

August 15, 2021

Castle Biosciences Announces Second Quarter 2021 Results

August 8, 2021

Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting

August 5, 2021

Castle Biosciences Collaborates with the Melanoma Research Foundation

August 1, 2021

Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021

July 25, 2021

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

July 22, 2021

Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021

July 21, 2021

Castle Biosciences Expands its Board of Directors with New Appointments

July 15, 2021

Castle Biosciences Announces Receipt of New York Laboratory Permit

June 8, 2021

Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters

May 23, 2021

Castle Biosciences Supports the American Skin Association with Research Grant

May 20, 2021

Castle Biosciences Announces First Quarter 2021 Results

May 9, 2021

Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

May 3, 2021

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

April 26, 2021

Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021

April 25, 2021

Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population

April 22, 2021

Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma

April 12, 2021

Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions

March 24, 2021

Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results

March 7, 2021

Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021

February 21, 2021

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

January 19, 2021

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

January 12, 2021

Castle Biosciences Announces Early Repayment of Debt

December 21, 2020

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 17, 2020

Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock

December 14, 2020

Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock

December 13, 2020

Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma

December 3, 2020

Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions

November 16, 2020

Castle Biosciences Announces Third Quarter 2020 Results

November 8, 2020

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

November 1, 2020

Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting

October 28, 2020

Castle Biosciences to Release Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 9, 2020

October 25, 2020

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

October 7, 2020

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

September 1, 2020

Castle Biosciences Announces Leadership Promotions and New Medical Director

August 31, 2020

Castle Biosciences Announces Second Quarter 2020 Results

August 9, 2020

Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma

July 14, 2020

Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

July 1, 2020

Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock

June 23, 2020

Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock

June 21, 2020

Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020

May 21, 2020

New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions

May 18, 2020

Castle Biosciences Announces First Quarter 2020 Results

May 10, 2020

Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma

May 4, 2020

Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma

April 28, 2020

Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020

April 26, 2020

Castle Biosciences Appoints Miles Harrison to Board of Directors

April 1, 2020

Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk

March 31, 2020

Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma

March 25, 2020

Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results

March 9, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.